SEGMENT INFORMATION

6 Months Ended

Mar. 31, 2013

SEGMENT INFORMATION [Abstract]

SEGMENT INFORMATION

6. SEGMENT INFORMATION

We operate in two principal segments - research services and research products. Our Services segment provides research and development support on a contract basis directly to pharmaceutical companies. Our Products segment provides liquid chromatography, electrochemical and physiological monitoring products to pharmaceutical companies, universities, government research centers and medical research institutions. Our accounting policies in these segments are the same as those described in the summary of significant accounting policies found in Note 2 to Consolidated Financial Statements in our annual report on Form 10-K/A for the year ended September 30, 2012.

	Three Months Ended March 31,						Six Months Ended March 31,
	2013			2012			2013			2012
	(Restated)			(Restated)			(Restated)			(Restated)
Revenue:
Service	$	3,667		$	5,279		$	8,337		$	10,890
Product		1,489			1,687			2,623			3,592
	$	5,156		$	6,966		$	10,960		$	14,482
Operating income (loss):
Service	$	(365	)	$	(1,419	)	$	(150	)	$	(2,685	)
Product		356			(275	)		444			(311	)
Corporate		-			(11	)		-			(11	)
	$	(9	)	$	(1,705	)	$	294		$	(3,007	)
Interest expense		(163	)		(179	)		(329	)		(368	)
Change in fair value of warrant liability - (increase) decrease		(142	)		56			(25	)		-
Other income		3			-			5			-
Income (loss) before income taxes	$	(311	)	$	(1,828	)	$	(55	)	$	(3,375	)

Restructuring costs of $53 and $11 are included in the operating losses for the three and six months ended March 31, 2012 for the Service and Corporate segments, respectively.